tofacitinib

AssetAlso called CP-690,550, tofacitinib, CGB-500, Tofacitinib Citrate

Janus kinase (JAK) inhibitor that suppresses inflammatory cytokine signaling

Stage
Phase 3
Modality
Small molecule
Target
JAK2
16
Indications
144
Trials
3
Developers

Trial NCT04624230 is still running. Trial NCT04624230 updated in its registry on Aug 3, 2026. clinicaltrials.gov

Indications

16

13 more

In the full profile

  • Target and mechanism4
  • Owner and partners3
  • Trials144
  • Evidence for its targets5
  • Competitors12
  • Aging relevance2
  • Signals15

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets